The strategic acquisition will strengthen access to care, enhance outcomes and support local healthcare teamsOTTAWA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a trusted provider of mission-critical solutions for defence, space and healthcare announced today it has acquired Advanced Medical Solutions (AMS), a leading provider of remote and emergency healthcare services in Northern Canada. The acquisition is effective immediately. About AMS Headquartered in Yellowknife, Northwest ...

Wall Street saw a strong rally on Monday, driven by renewed optimism over U.S.-China trade relations. A 90-day agreement between the two nations to reduce tariffs has rekindled hopes of easing global trade tensions. The United States will lower duties on Chinese imports from a steep 145% to 30%, while China has agreed to cut its retaliatory tariffs on American goods from 125% to 10%, signaling a shift from confrontation to cooperation.Markets responded positively, with the S&P 500 jumping 3.3% to settle at ...

Surgery Partners (SGRY) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Dave Doherty - EVP & CFOEric Evans - CEOBenjamin Rossi - Equity Research AssociateAndrew Mott - Director, Team Leader and Co-Head of Private BankA.J. Rice - Managing DirectorWhit Mayo - Senior Managing DirectorBen Hendrix - Vice President Conference Call Participants Brian Tanquilut - Equity Research Analyst - Healthcare ServicesJoanna Gajuk - Equity Research AnalystSarah James - Managing Director & Equity Analyst - ...

Doximity (DOCS) is scheduled to release fourth-quarter fiscal 2025 results on May 15, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 36.36%. DOCS delivered a trailing four-quarter average earnings surprise of 26.00%.DOCS Q4 EstimatesCurrently, the consensus estimate for revenues is pegged at $133.8 million. The consensus mark for earnings is pinned at 27 cents per share.Factors to NoteDoximity’s fourth-quarter fiscal 2025 performance is expected ...

Industry Overview - The healthcare industry has faced challenges in early 2025, including concerns over potential cuts to Medicare and Medicaid, as well as the impact of tariffs on supplies [1] - Despite these challenges, healthcare stocks have performed relatively well, with the Health Care Select Sector SPDR Fund (XLV) down less than 2% year-to-date, compared to the S&P 500's decline of nearly 3% [1] Company Analysis: Centene - Centene Corp. (CNC) has shown solid membership and revenue growth, primarily driven by its Medicaid services, which have helped it withstand market volatility [3][4] - For Q1 2025, Centene reported a 29% year-over-year increase in Marketplace membership and a 22% increase in Medicare membership, contributing to a 28% improvement in adjusted diluted earnings per share (EPS) and a 17% growth in premium and service revenue [4] - The company has reiterated its full-year guidance, indicating optimism for future performance [4] Company Analysis: Tenet Healthcare - Tenet Healthcare Corp. (THC) has received positive analyst ratings, with 13 Buy ratings and four Holds, following a strong Q1 2025 earnings report that exceeded EPS estimates by $1.25 per share, reflecting a year-over-year improvement of over 35% [6][7] - The company plans to invest $250 million annually in its Ambulatory segment and has opened six new centers in Q1 2025, which are expected to drive continued growth [8] - Tenet's share repurchase program and efforts to improve its balance sheet are anticipated to enhance shareholder value [8] Company Analysis: Encompass Health - Encompass Health Corp. (EHC) reported better-than-expected earnings, leading to increased price targets from analysts [10] - The company's shares have risen over 25% year-to-date, with expectations of 10% projected earnings growth in the near term [11]

First Quarter 2025 May 2025 Earnings Supplement Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward- looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, estimates of our total addressable market, our abi ...

Astrana Health (ASTH) Q1 2025 Earnings Call May 08, 2025 05:30 PM ET Company Participants Brandon Sim - President & CEOChan Basho - CFO & COORyan Daniels - Group Head–Healthcare Technology and ServicesJack Slevin - VP - Healthcare Services Equity ResearchJailendra Singh - Managing DirectorDavid Larsen - Managing DirectorZach Haggerty - Equity Research AssociateThomas Walsh - Equity Research Associate Conference Call Participants Michael Ha - Senior Research AnalystRyan Langston - Director & Senior Analyst - ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $650.7 million, down 5% year over year and 2% sequentially, primarily due to known NEMT contract attrition, lower build hours in PCS, and membership churn in monitoring [20][21] - Net loss for the quarter was $50.4 million, up from $22.3 million a year ago, mainly due to higher interest expense which rose to $38.8 million [21] - Adjusted net loss was $24.5 million or negative $1.71 per share, reflecting the exclusion of restructuring-related costs and amortization of intangibles [21] - Adjusted EBITDA was $32.6 million, essentially flat year over year but down sequentially, with key drivers including an $8 million impact from net NEMT contract development [21][22] Business Line Data and Key Metrics Changes - In NEMT, revenue was $449 million, representing 69% of total revenue, declining 6% year over year due to previously disclosed contract losses [22] - Average monthly members in NEMT declined 19% year over year and 20% sequentially, while utilization from the normalization of healthcare increased to 12% [22] - PCS contributed $181.8 million in revenue or 28% of total revenue, with revenue per hour rising 1.1% while service hours declined 2.1% due to expected seasonality [24] - Monitoring contributed $18.1 million in revenue, representing just 3% of total revenue but 16% of total adjusted EBITDA, with adjusted EBITDA at $5.2 million for a 29% segment margin [25] Market Data and Key Metrics Changes - The broader opportunity in the 2026 pipeline exceeds $500 million in potential contract value, with the company experiencing a loss of a regional contract totaling $15 million in annual revenue [6][7] - In Indiana, referral volume increased by more than 45% year over year, while new Southeastern markets delivered sequential growth [9] Company Strategy and Development Direction - The company aims to grow and retain core customer relationships, digitize and automate the Care Access platform, optimize the operating model for simplicity and scale, increase capital efficiency, and deliver high-impact client-centric supportive care [4][5] - The long-term vision is to become the digital infrastructure for supportive care, unifying fragmented benefits and delivering a coordinated member experience [19] Management's Comments on Operating Environment and Future Outlook - Management noted that the decline in revenue was expected and reflects prior year customer transitions and market dynamics that are largely behind the company [20] - The company is focused on executing against measurable initiatives and communicating progress through clear objective KPIs and milestones, without issuing formal guidance for 2025 [28] Other Important Information - The company launched a company-wide G&A reduction initiative targeting approximately $25 million in annualized savings [14] - The net contracts receivable rose to $109 million, up from $95 million in Q4, due to expected billing timing [26] Q&A Session Summary Question: How should cash flow generation be modeled for the rest of the year? - Management indicated that EBITDA is driving cash flow and expects meaningful improvement in cash flow generation as the year progresses, particularly due to contract restructuring and working capital improvements [31][38] Question: Why did contract receivables increase despite a decline in revenue? - The increase in accounts receivable was attributed to the contract mix and shared risk contracts that have not yet been converted [39][40] Question: Is there a positive cash flow possibility in Q3? - Management acknowledged that due to large debt payments in Q2 and Q4, positive cash flow from operations may not be achievable in those quarters, but they feel good about cash flow generation for the year overall [51][54] Question: Can you elaborate on the G&A savings? - The $25 million in G&A savings primarily comes from labor efficiencies within corporate and shared service areas as the company continues to streamline operations [57][59]

Evolent Health (EVH) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Welcome to the Evolent Earnings Conference Call for the First Quarter Ended 03/31/2025. As a reminder, this conference call is being recorded. Your hosts for the call today from Evolent are Seth Blackley, Chief Executive Officer and John Johnson, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the company's website in the section titled Investor Relations ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 16.5% to $324 million in the first quarter, driven by an increase in the number of clients and covered lives compared to the previous year [17] - Adjusted EBITDA grew 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [24][25] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [25] Business Line Data and Key Metrics Changes - Fertility revenue increased by 22% to $206 million, while pharmacy revenue grew by 9% to $118 million [22] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [21] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 increased, indicating a shift in family planning trends [8][9] - More than 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity services [10] Company Strategy and Development Direction - The company is focused on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [6][11] - The company aims to deepen relationships with existing clients, with 20% to 25% of the base typically taking additional services [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current engagement levels and the pipeline for new clients, despite some macroeconomic uncertainties [12][13] - The company raised its full-year revenue guidance to between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [29] Other Important Information - The company generated nearly $50 million in operating cash flow, nearly double the prior year period [25] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [27] Q&A Session Summary Question: Inquiry about historical seasonality of cycles per utilizer - Management indicated that the guidance reflects uncertainty rather than a change in normal seasonality [32] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and they expect gross margin expansion for the full year compared to 2024 [33][35] Question: Comments on the 2026 selling season and RFP processes - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [40][43] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and they have flexibility in arrangements with clients to mitigate potential increases [54] Question: Pricing benefits in ART cycles - Management clarified that growth is primarily driven by engagement and consumption rather than pricing [69]